No connection

Search Results

APYX

BULLISH
$3.63 Live
Apyx Medical Corporation · NASDAQ
Target $6.4 (+76.3%)
$0.76 52W Range $4.5

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Mar 14, 2026
Market cap
$148.94M
P/E
N/A
ROE
-76.1%
Profit margin
-21.2%
Debt/Equity
2.65
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
APYX exhibits a weak Piotroski F-Score of 1/9, signaling significant financial distress and poor operational health, with negative ROE, ROA, and high debt/equity. Despite this, the company demonstrates strong revenue growth (34.7% YoY) and a compelling earnings surprise history, with recent quarters beating estimates by an average of 33.74%. The stock is trading at a premium valuation (Price/Book: 10.43, Price/Sales: 2.82) but is supported by a strong analyst consensus of 'strong_buy' and a target price of $6.40, implying significant upside. Insider activity remains neutral, but the recent 1-year return of +249% reflects strong market momentum. The absence of a Graham Number and Altman Z-Score limits fundamental safety checks, but growth expectations appear to justify the valuation premium.

Key Strengths

Strong revenue growth of 34.7% YoY
Consistent earnings beat history with average surprise of 33.74% over last 4 quarters
High analyst consensus with 'strong_buy' rating and $6.40 target price
Significant recent price appreciation (+249% over 1 year)
High gross margin of 62.53% indicating pricing power and efficient production

Key Risks

Piotroski F-Score of 1/9 indicates severe financial distress and poor operational quality
Negative ROE (-76.15%) and ROA (-6.12%) reflect deep profitability issues
Debt/Equity ratio of 2.65 is high, especially for a company with negative earnings
No Altman Z-Score available, but the financial health metrics suggest distress risk
Negative profit margin (-21.22%) and lack of positive operating cash flow or free cash flow data

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
44
Moderate
Value
45
Future
82
Past
70
Health
25
Dividend
0
AI Verdict
cautiously bullish
Key drivers: Strong revenue and earnings surprise momentum, High growth expectations priced in, Positive technical trend and strong price performance
Confidence
85%
Value
45/100

Ref P/E, PEG, Graham Number

Positives
  • Price/Sales of 2.82 is below sector average of 137.13% revenue growth, suggesting potential undervaluation relative to growth
  • Forward P/E of -12.74 implies market pricing in future profitability
Watchpoints
  • No Graham Number or intrinsic value estimate available
  • Price/Book of 10.43 is extremely high for a company with negative ROE and profitability
  • Lack of positive cash flow metrics undermines valuation reliability
Future
82/100

Ref Growth rates

Positives
  • 34.7% YoY revenue growth is robust and consistent
  • Recent Q/Q EPS growth of +40.0% and YoY EPS growth of +75.0% indicate accelerating profitability
  • Strong earnings surprise history suggests strong execution and guidance accuracy
Watchpoints
  • Forward P/E is negative, indicating no near-term earnings visibility
  • No free cash flow or operating cash flow data to validate growth sustainability
Past
70/100

Ref Historical trends

Positives
  • 25 quarters of earnings data show consistent beat rate (3/4 in last 4 quarters)
  • Average earnings surprise of 33.74% over last 4 quarters is exceptional
  • Recent quarters show improving EPS trends despite negative baseline
Watchpoints
  • Long-term negative earnings trend with persistent losses
  • Historical losses and negative ROE/ROA indicate structural profitability issues
Health
25/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • High current and quick ratios (5.00 and 4.16) suggest strong short-term liquidity
  • No immediate cash crunch risk despite negative earnings
Watchpoints
  • Piotroski F-Score of 1/9 is extremely low, indicating severe financial weakness
  • Negative ROE (-76.15%) and ROA (-6.12%) signal poor capital efficiency
  • Debt/Equity of 2.65 is high for a non-profitable firm
  • No Altman Z-Score available, but financials suggest distress risk
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend yield or payout ratio
  • Dividend Strength score of 0/100 confirms no dividend policy

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$3.63
Analyst Target
$6.4
Upside/Downside
+76.3%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for APYX and closest competitors.

Updated 2026-03-13
APY
Apyx Medical Corporation
Primary
5Y
-68.5%
3Y
+28.3%
1Y
+249.0%
6M
+72.9%
1M
-7.4%
1W
+16.4%
NYX
Nyxoah SA
Peer
5Y
-85.9%
3Y
-65.9%
1Y
-43.6%
6M
-44.6%
1M
+7.1%
1W
+11.4%
AGE
Agenus Inc.
Peer
5Y
-93.5%
3Y
-88.0%
1Y
+124.2%
6M
-10.7%
1M
+36.6%
1W
+18.4%
TLS
Tiziana Life Sciences Ltd
Peer
5Y
-51.0%
3Y
+16.4%
1Y
+7.1%
6M
-38.3%
1M
0.0%
1W
+5.2%
EMP
Empro Group Inc.
Peer
5Y
+299.1%
3Y
+299.1%
1Y
+299.1%
6M
-2.2%
1M
0.0%
1W
0.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-12.74
PEG Ratio
N/A
P/B Ratio
10.43
P/S Ratio
2.82
EV/Revenue
3.02
EV/EBITDA
-27.58
Market Cap
$148.94M

Profitability

Profit margins and return metrics

Profit Margin -21.21%
Operating Margin 0.06%
Gross Margin 62.53%
ROE -76.15%
ROA -6.12%

Growth

Revenue and earnings growth rates

Revenue Growth +34.7%
Earnings Growth N/A
Q/Q Revenue Growth N/A
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
2.65
High debt
Current Ratio
5.0
Strong
Quick Ratio
4.16
Excellent
Cash/Share
$0.76

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-03-10
$-0.03
+46.4% surprise
2025-11-06
$-0.05
+51.2% surprise
2025-08-07
$-0.09
+3.6% surprise

Healthcare Sector Comparison

Comparing APYX against 560 companies in the Healthcare sector (34 bullish, 167 neutral, 359 bearish)
Return on Equity (ROE)
-76.15%
This Stock
vs
-88.14%
Sector Avg
-13.6% (Below Avg)
Profit Margin
-21.21%
This Stock
vs
-16.28%
Sector Avg
+30.3% (Superior)
Debt to Equity
2.65
This Stock
vs
2.66
Sector Avg
-0.4% (Lower)
Revenue Growth
34.7%
This Stock
vs
124.04%
Sector Avg
-72.0% (Slower)
Current Ratio
5.0
This Stock
vs
4.47
Sector Avg
+11.7% (Better)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

ROMAN SHAWN DAVID
Chief Operating Officer
Option Exercise
2026-01-27
12,000 shares · $21,600
Insider transactions can signal confidence or concerns about company prospects

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
STRONG_BUY
5 analysts
Craig-Hallum
2026-03-11
Maintains
Buy Buy
BTIG
2026-03-11
up
Neutral Buy
Roth Capital
2025-12-16
init
Buy
Citizens
2025-11-12
up
Market Perform Market Outperform

Past News Coverage

Recent headlines mentioning APYX from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI Chat
Markets
Profile